Clinical experience with cranial nerve impairment in the CARTITUDE-1, CARTITUDE-2 cohorts A, B, and C, and CARTITUDE-4 studies of ciltacabtagene autoleucel (cilta-cel)

Last Updated: Thursday, July 10, 2025

An evaluation of the presentation and management of cranial neuropathy in patients treated with ciltacabtagene autoleucel (cilta-cel) across the CARTITUDE-1, -2, and -4 trials. Out of 332 patients receiving cilta-cel across the trials, 21 patients (6.3%) developed cranial neuropathy. Most cases were low grade and were resolved with corticosteroids.

Transplantation and Cellular Therapy

Neurotoxicity and rare adverse events in BCMA-directed CAR T cell therapy: A comprehensive analysis of real-world FAERS data

Transplantation and Cellular Therapy

Clinical experience with cranial nerve impairment in the CARTITUDE-1, CARTITUDE-2 cohorts A, B, and C, and CARTITUDE-4 studies of ciltacabtagene autoleucel (cilta-cel)

Nature Medicine

Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: A phase 1 trial

Blood Advances

Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel

Blood Advances

Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma

Journal of Clinical Oncology

Comparison of standard-of-care idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed/refractory multiple myeloma

Cancer Cell

Restoration of LAT activity improves CAR T cell sensitivity and persistence in response to antigen-low acute lymphoblastic leukemia

Pediatric Blood & Cancer

Neuropsychological functioning in pediatric patients with leukemia or lymphoma treated with CAR T-cell therapy: A retrospective chart review

Leukemia

Anti-CD19 CAR-T cell therapy for acquired hemophilia A

Brain

Current state and perspectives of CAR T-cell therapy in central nervous system diseases

CAR T-Cell Therapy Resource Center

Clinical experience with cranial nerve impairment in the CARTITUDE-1, CARTITUDE-2 cohorts A, B, and C, and CARTITUDE-4 studies of ciltacabtagene autoleucel (cilta-cel)

Transplantation and Cellular Therapy

Neurotoxicity and rare adverse events in BCMA-directed CAR T cell therapy: A comprehensive analysis of real-world FAERS data

Transplantation and Cellular Therapy

Clinical experience with cranial nerve impairment in the CARTITUDE-1, CARTITUDE-2 cohorts A, B, and C, and CARTITUDE-4 studies of ciltacabtagene autoleucel (cilta-cel)

Nature Medicine

Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: A phase 1 trial

Blood Advances

Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel

Blood Advances

Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma

Journal of Clinical Oncology

Comparison of standard-of-care idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed/refractory multiple myeloma

Cancer Cell

Restoration of LAT activity improves CAR T cell sensitivity and persistence in response to antigen-low acute lymphoblastic leukemia

Pediatric Blood & Cancer

Neuropsychological functioning in pediatric patients with leukemia or lymphoma treated with CAR T-cell therapy: A retrospective chart review

Leukemia

Anti-CD19 CAR-T cell therapy for acquired hemophilia A

Brain

Current state and perspectives of CAR T-cell therapy in central nervous system diseases

Bloodless Medicine Management of a Patient Receiving CAR T-Cell Therapy

Transverse Myelitis With Paraplegia: An Atypical Manifestation of Neurotoxicity Following CAR T-Cell Therapy

CAR T-cell Infusion in an Outpatient Setting: An Ideal Option for Selected Patients When Available

Fast Facts #12: BCMA Targets